Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 27 current clinical trials in our China register. 13 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Anlotinib, Butylphthalide and Fluoxetine. The most-studied condition is Robotic Surgical Procedures.

ClinicalTrials.gov trials by status

Recruiting1348%
Not yet open1348%
Active, closed14%

Trials by phase

Not applicable726%
Phase 2622%
Observational519%
Phase 4519%
Phase EARLY_PHASE127%
Phase 1/214%
Phase 314%

Clinical trials sponsored by First Affiliated Hospital of Wenzhou Medical University

27 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety NCT07174947 · ClinicalTrials.gov ↗ · Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders Drug: Fluoxetine	Phase 2	Recruiting	2025-10	China
Study on Aging and Cognitive Impairment in China NCT06679296 · ClinicalTrials.gov ↗ · Cognitive Dysfunction, Aging	Observational	Recruiting	2024-11	China
Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports NCT07707232 · ClinicalTrials.gov ↗ · Prostate Cancer	Observational	Recruiting	2026-06	China
Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial NCT07586384 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Robotic Surgical Procedures	Not applicable	Recruiting	2025-11	China
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy NCT07193277 · ClinicalTrials.gov ↗ · Focal Epilepsy, Cognitive Impairment Drug: Butylphthalide	Phase 4	Recruiting	2025-09	China
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities NCT07381634 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), IrAE Drug: Ondansetron	Phase 2	Recruiting	2026-04	China
Noninvasive Prediction of Portal Hypertension in Cirrhosis Using Sound Touch Viscoelastography NCT06316869 · ClinicalTrials.gov ↗ · Portal Hypertension, Cirrhosis	Observational	Recruiting	2024-09	China
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma NCT07495735 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma	Observational	Recruiting	2026-03	China
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） NCT06368882 · ClinicalTrials.gov ↗ · Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b	Phase 4	Recruiting	2024-01	China
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection NCT06052033 · ClinicalTrials.gov ↗ · HPV-Related Cervical Carcinoma, Low-Grade Squamous Intraepithelial Lesions, HPV Infection	Not applicable	Recruiting	2023-09	China
Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs NCT07604896 · ClinicalTrials.gov ↗ · Alzheimer s Disease, Alzheimer Dementia (AD), MCI-AD, Early Stage Alzheimer's Disease Drug: Lecanemab	Phase 4	Recruiting	2026-01	China
Dual-port Trans-subclavian Thyroid Endoscopic Surgery NCT06398795 · ClinicalTrials.gov ↗ · Thyroid Neoplasms, Endoscopic Surgery	Not applicable	Recruiting	2022-09	China
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer NCT07347951 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Phase 2	Recruiting	2025-12	China
Intelligent Precision Knee Preservation System for Knee Osteoarthritis NCT07284524 · ClinicalTrials.gov ↗ · Knee Osteoarthritis (Knee OA)	Not applicable	Not yet open	2026-01	China
Preoperative vs Postoperative Revascularization in Coronary Heart Disease Patients Undergoing Time-Sensitive Non-Cardiac Surgery (CHRONOS-PCI) NCT07175870 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Noncardiac Surgery	Not applicable	Not yet open	2025-10	China
Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy NCT07815301 · ClinicalTrials.gov ↗ · Obstructive Hypertrophic Cardiomyopathy (oHCM)	Not applicable	Not yet open	2026-12	China
Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study NCT07151456 · ClinicalTrials.gov ↗ · Idiopathic Nephrotic Syndrome	Phase 4	Not yet open	2026-01	China
Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia NCT07827521 · ClinicalTrials.gov ↗ · Chronic Limb-Threatening Ischemia, Diabetic Foot Ulcer, Infrapopliteal Arterial Occlusive Disease	Phase 4	Not yet open	2026-10	China
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases NCT06420154 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis	Phase EARLY_PHASE1	Not yet open	2024-05	China
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study NCT07189793 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder Drugs: Gemcitabine, Mitomycin C, Toripalimab	Phase 2	Not yet open	2026-12	China
Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer NCT07254858 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer	Phase 2	Not yet open	2025-12	China
Assessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound NCT06309082 · ClinicalTrials.gov ↗ · Diabetes Mellitus	Observational	Not yet open	2024-11	China
Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence NCT07831187 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 1/2	Not yet open	2026-10	China
Edaravone Dexborneol for Post-Stroke Epilepsy NCT07604350 · ClinicalTrials.gov ↗ · Post-stroke Epilepsy, Post-stroke Seizure	Phase 3	Not yet open	2026-06	China
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer NCT07394205 · ClinicalTrials.gov ↗ · Advanced Gastric and Pancreatic Cancer	Phase EARLY_PHASE1	Not yet open	2026-09	China
Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer NCT07828899 · ClinicalTrials.gov ↗ · STOMACH NEOPLASM, Robotic Surgical Procedures	Not applicable	Not yet open	2026-10	China
Anlotinib Capsules in the Treatment for IPF/PF-ILDs NCT05828953 · ClinicalTrials.gov ↗ · Interstitial Lung Diseases Drug: Anlotinib	Phase 2	Active, closed	2021-09	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in First Affiliated Hospital of Wenzhou Medical University trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Anlotinib1 Butylphthalide1 Fluoxetine1 Gemcitabine1 Lecanemab1 Mitomycin C1 Ondansetron1 Toripalimab1

Conditions in First Affiliated Hospital of Wenzhou Medical University trials

53 conditions

Robotic Surgical Procedures2Knee Osteoarthritis (Knee OA)1Coronary Artery Disease1Noncardiac Surgery1Hepatobiliary Malignancy1Fluoxetine1Anxiety Disorders1Depression Disorders1Cognitive Dysfunction1 Aging1 Prostate Cancer1Obstructive Hypertrophic Cardiomyopathy (oHCM)1Idiopathic Nephrotic Syndrome1Stomach Neoplasms1 Focal Epilepsy1 Cognitive Impairment1Chronic Limb-Threatening Ischemia1Diabetic Foot Ulcer1Infrapopliteal Arterial Occlusive Disease1Systemic Lupus Erythematosus (SLE)1Sjogren's Syndrome1Systemic Sclerosis1 Inflammatory Myopathy1Interstitial Lung Diseases1

By trial register

Register	Trials	Recruiting
Clinical trials in China	27	13

A trial with sites in more than one country appears in each of those registers.

Questions about First Affiliated Hospital of Wenzhou Medical University trials

How many clinical trials does First Affiliated Hospital of Wenzhou Medical University sponsor?

First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 27 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are First Affiliated Hospital of Wenzhou Medical University trials recruiting?

Yes. 13 of its 27 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is First Affiliated Hospital of Wenzhou Medical University testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are Anlotinib (1), Butylphthalide (1), Fluoxetine (1), Gemcitabine (1) and Lecanemab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

First Affiliated Hospital of Wenzhou Medical University clinical trials